Phio Pharmaceuticals Corp. (PHIO) Stock Price & Analysis
Phio Pharmaceuticals Corp. (PHIO) closed at USD 0.85 on Friday, October 23, 2026, down 2.30% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.85; the Oct 23, 2026 session ranged USD 0.85–0.9 on volume of 28,713 shares. Market capitalization is —, with a 52-week range of USD 0.81–4.19 (NCM). Source: Nexqual, retrieved October 24, 2026 at 12:39 UTC.
Also available as compact Markdown for AI agents: nexqual.com/PHIO.md
Key facts (PHIO)
- Total return with dividends: 1Y -59.8% vs S&P 500 +13.4%; 5Y -99.5% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (PHIO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$13.5M | -$11.5M | -$10.8M | -$7.4M | -$9.2M | -$13.5M |
| Net income | -$13.3M | -$11.5M | -$10.8M | -$7.2M | -$8.7M | -$12.9M |
| EPS (diluted) | -$111.87 | -$90.90 | -$46.76 | -$9.08 | — | — |
| Free cash flow | -$11.9M | -$12.3M | -$10.8M | -$7.1M | -$8.0M | -$12.2M |
| Cash + short-term investments | $24.1M | $11.8M | $8.5M | $5.4M | $21.0M | — |
| Total debt | $0K | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (PHIO)
Analysts (PHIO)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-26 | HC Wainwright & Co. | Reiterated | Buy | $14 |
Total return (dividends reinvested) (PHIO)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -59.8% | -99.5% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -59.9% | -65.8% |
| Volatility (annualized) | 77.8% | 108.2% |
| Max drawdown | -60.6% (Oct 2025→Oct 2026) | -99.7% (Apr 2022→Oct 2026) |
PHIO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.36 | $-0.33 | +10.8% | $0 | 2 |
| Next quarter (ends Dec 2026) | $-0.39 | $-0.35 | +10.0% | $0 | 2 |
| Current fiscal year (ends Dec 2026) | $-1.45 | $-1.38 | +5.1% | $0 | 2 |
| Next fiscal year (ends Dec 2027) | $-0.61 | $-0.86 | -29.1% | $0 | 2 |
Key Statistics (as of October 24, 2026 at 12:39 UTC)
| Price | USD 0.85 |
|---|---|
| Change | ▼ 2.30% (down) |
| Previous Close | USD 0.85 |
| Open | USD 0.85 |
| Day Range | USD 0.85 – 0.9 |
| 52-Week Range | USD 0.81 – 4.19 |
| Volume | 28,713 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (PHIO)
Nexqual's technical model rates PHIO "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 12:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 28.22 (oversold) |
| vs SMA50 | Below (USD 1.03) |
| MACD | -0.04 (negative) |
Earnings (PHIO)
| EPS Estimate | USD -0.36 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.36 vs est -0.36 ▲ beat |
| 2026-03-31 | USD -0.34 vs est -0.24 ▼ miss |
| 2025-12-31 | USD -0.15 vs est -0.47 ▲ beat |
| 2025-09-30 | USD -0.44 vs est -0.44 ▲ beat |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Financials & Fundamentals (PHIO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -113.71% |
| Current Ratio | 8.39 |
| Total Cash | $13.00M |
| Total Debt | $0 |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Ownership (PHIO)
| Insider Ownership | +8.01% |
|---|---|
| Institutional Ownership | +10.21% |
| Shares Outstanding | 11.62M |
| Float | 11.26M |
| Short % of Float | +0.77% |
Source: Nexqual, October 24, 2026 at 12:39 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 303.53 | ▼ 1.39% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 89.27 | ▼ 1.79% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.09 | ▼ 0.35% |
| PRAX | Praxis Precision Medicines, Inc | USD 252.96 | ▼ 2.3% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.93 | ▼ 2.23% |
| AXSM | Axsome Therapeutics, Inc. | USD 145.04 | ▼ 7.07% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 12:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt